Meet the speaker at the ASN Kidney Week, October 23 – 28, San Diego, CA
Dr. Maulik Shah will talk about “A nuclear magnetic resonance-based method for accurate assessment of glomerular filtration rate”, October 25 at 5:54 pm, Session “Harnessing Molecular, Machine-Learning, and Genomic Innovation in Pathology”.
Get in contact with us to arrange an appointment with the speaker here.
AXINON® is the first modular software-based system providing hardware, operating system, MGS® processor and individual test applications, collectively enabling:
Innovative real-time use of metabolic data
Precise results for specific medical questions and diagnostic decisions
High throughput capability
Fully automated lab solution
High reproducibility (inter-laboratory precision)
Connectivity to lab systems (LIS/LIMS)
Easy-to-use (no special NMR skills required)
Applications of the AXINON® System
AXINON® System provides a more detailed and standardized analysis of the lipoprotein subclasses, beyond the standard lipid panel, via Magnetic Group Signaling (MGS®) technology. The test system measures concentration, size and distribution of lipoprotein particles (which carry cholesterol) for the assessment of cardiovascular risk. To date, more than 1.5 million tests have been performed using numares’ technology.
numares AXINON® lipoFIT® – S100 system can also determine the respective quantity of the key compounds triglycerides, cholesterol and phospholipids. For Research Use only in the United States.
numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.
AXINON® renalTX-SCORE® -U100 – A non-invasive test for the diagnosis of kidney transplant allograft
AXINON ® renalTX-SCORE® -U100 is a urine based test using metabolomics and Magnetic Group Signaling (MGS®) technology to support the diagnosis of a kidney transplant allograft rejection. This non-invasive test analyzes and evaluates a metabolic biomarker network previously identified and validated that is indicative of transplant rejection. Thus, this test allows for close-monitoring of the transplant allograft, is non-invasive for greater patient compliance and comfort and does not require potential graft damaging biopsy. In the course of follow-up care and in conjunction with clinical context, AXINON® renalTX- SCORE® -U100 can identify graft rejection reactions and clarify the cause of non-specific symptoms.
Trusted technology for reliable results
To date, more than 1.5 million tests have been performed in the U.S. using the numares’ technology platform.
How does the test work?
The AXINON® renalTX-SCORE® -U100 test is performed on the AXINON® system which produces high-quality, standardized NMR spectra based on numares’ Magnetic Group Signaling (MGS®) technology. These are evaluated by test-specific software to deliver reproducible results.
Easy, fast and efficient
The combination of MGS® with the AXINON® technology platform allows for test-specific spectral analysis with highly-reproducible results. The system is easy to use with one-step sample preparation with ready-to-use reagents requiring minimal operator interaction. The test system is fast and efficient with automation capabilities allowing short hands-on-time and high walk-away capability with a throughput of more than 175 samples per day. For Research Use only in the United States. numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.
(in development) numares is developing a serum test to significantly improve serum creatinine-based glomerular filtration rate (GFR) estimation to allow for a more accurate assessment of renal (kidney) function. This would improve the treatment of patients with renal diseases and monitoring of therapies with nephrotoxic drugs.
(in development) numares currently focuses its research activities on bladder, prostate, and hepatic cellular cancer. The objective is to find metabolic biomarker profiles indicating the presence of cancer, which could be used in diagnostic screening.
(in development) In collaboration with Oxford University, numares is evaluating a metabolic constellation to monitor relapsing-remitting multiple sclerosis (RRMS) patients for the transition to the progressive form (secondary-progressive MS, SPMS). The transition to SPMS can only be diagnosed retrospectively since there is no diagnostic test currently available.
AXINON® is powered by Magnetic Group Signaling (MGS®) technology utilizing A.I. in metabolomics
The NMR based AXINON® System offers high throughput multi-testing capability
AXINON® enables a more detailed, standardized and automated lipoprotein and metabolite profiling
Identification of more than 400 metabolites within one run enables the discovery of meaningful metabolic constellations / profiles
Advanced. Automated. Affordable.
One Sample – All Answers
Mastering Metabolic Networks for Real-Time Precision Medicine
Currently, clinical diagnostics are pathway and pattern-based using single biomarkers and chemistry-based analytics that are complex and often times expensive.
The industry is shifting to system-wide medicine, leveraging disease-associated biomarker networks, software-based analytics, simpler sample preparation resulting in actionable clinical decision support and precision medicine.
Importance of Metabolomics
The concentration of metabolic products (metabolites) in various body fluids depends on the genetic and environmental exposure of a human being.
This individual metabolic pattern is subject to normal physiological variation, but may also reflect pathological processes in the body.
Nuclear magnetic resonance (NMR) spectroscopy is the method of choice to detect metabolic constellations, as NMR allows the simultaneous quantification of ~400 metabolites in human specimens.
An NMR spectrum reflects all organic substances in a sample. This allows for the determination of the structure and dynamics of molecules and determination of substance concentrations within a single run.
Magnetic Group Signaling
Biological samples evaluated on different NMR machines can produce different results. Magnetic Group Signaling (MGS®) standardizes NMR systems and sample processing to ensure reproducible results on different NMR instruments.
numares is a fast-growing innovative diagnostics company that develops and markets software-based test systems for high throughput use in clinical diagnostics and life science research.
The AXINON® System and its individual diagnostic tests employ nuclear magnetic resonance (NMR) spectroscopy creating a “numaric” spectrum to evaluate metabolic networks. The output from these analyses provides physicians valuable information on the disease status of patients.
numares developed its proprietary Magnetic Group Signaling (MGS®) technology to enable NMR for highly standardized and rapid throughput testing, forming a cost-effective new solution for real-time diagnostic purposes. The metabolic tests have the potential to address unmet medical needs in various field such as cardiovascular diseases, nephrology, oncology and neurology, shaping an important pillar in precision medicine.
Locations: Boston, MA; Regensburg, GE; Singapore
employees of medical and scientific disciplines
Founded as a spin-off of Regensburg University
analyses worldwide with numares technology
numares GROUP Corporation
21 Drydock Ave
Boston, MA 02210, USA
Dr. Claus Botzler
For Research Use only in The United States. “numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.”